Adam Boxer, MD
Neurology · San Francisco, CANPI 1841231800
Payments from drug & device makers
Across 230 payments — averaging $23,742 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$2.6M
- Regeneron$1.5M
- Eisai Inc.$939K
- F. Hoffmann-la Roche AG$181K
- Genentech, Inc.$169K
- H. Lundbeck A S$37K
- plus $83K from 19 others
Across 3 payments — averaging $4618.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$13K
- Eli Lilly$810
What the payments were for
- Consulting fees$74,54657%
- Speaking & faculty fees$24,29019%
- Travel & lodging$27,81421%
- Food & beverage$3,3453%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 22 | $2,584,944 |
| Regeneron | 6 | $1,467,279 |
| Eisai Inc. | 60 | $938,972 |
| F. Hoffmann-la Roche AG | 13 | $180,648 |
| Genentech, Inc. | 17 | $169,018 |
| H. Lundbeck A S | 11 | $36,675 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 6 | $27,718 |
| Merck | 16 | $13,558 |
| Janssen Global Services, LLC | 11 | $9,971 |
| Eli Lilly | 18 | $7,104 |
| Janssen Research & Development, LLC | 10 | $6,315 |
| E.r. Squibb & Sons, L.L.C. | 3 | $3,152 |
| Pfizer | 1 | $2,450 |
| Roche Products Limited | 2 | $2,400 |
| Genentech USA, Inc. | 1 | $2,070 |
| Johnson & Johnson | 5 | $2,000 |
| Boehringer Ingelheim International GmbH | 1 | $2,000 |
| AstraZeneca | 1 | $1,500 |
| GSK | 2 | $1,380 |
| UCB Biosciences Inc. | 1 | $500 |
| Neurocrine Biosciences, Inc. | 8 | $423 |
| Boston Scientific | 5 | $239 |
| Otsuka Pharmaceutical Co., Ltd. | 8 | $197 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $105 |
| UCB SA | 1 | $38 |
How this compares
$5,460,656 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Donepezil Hcl | 16 | $115 |
| Citalopram HbrCitalopram Hydrobromide | 12 | $31 |
Paid to pharmacies, not to this prescriber.
Other neurology in San Francisco
- Bruce CreeSan Francisco$8M
- Stanley PrusinerSan Francisco$6.5M
- Jennifer ClarkeSan Francisco$5.1M
- Nancy Ann Oberheim BushSan Francisco$4.6M
- Emmanuelle WaubantSan Francisco$3M
- Jill OstremSan Francisco$2M
- William JagustSan Francisco$2M
- Gil RabinoviciSan Francisco$1.9M
- Jonathan KatzSan Francisco$1.7M
- Julio Rojas-MartinezSan Francisco$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.